DaBomb Protein Biotech Corp. (TPEX:6578)
Taiwan
· Delayed Price · Currency is TWD 18.05
-0.05 (-0.28%)
Mar 9, 2026, 1:30 PM CST
DaBomb Protein Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 310.11 | 337.82 | 384.41 | 433.63 | 470.63 | 605.22 | Upgrade
|
| Revenue Growth (YoY) | -13.07% | -12.12% | -11.35% | -7.86% | -22.24% | -6.40% | Upgrade
|
| Cost of Revenue | 242.75 | 269.1 | 337.99 | 414.3 | 448.98 | 505.95 | Upgrade
|
| Gross Profit | 67.35 | 68.73 | 46.43 | 19.33 | 21.65 | 99.27 | Upgrade
|
| Selling, General & Admin | 67.91 | 55.6 | 62.77 | 69.95 | 73.61 | 69.74 | Upgrade
|
| Research & Development | 16.83 | 14.95 | 13.59 | 11.85 | 11.82 | 14.15 | Upgrade
|
| Operating Expenses | 84.73 | 70.55 | 76.36 | 81.8 | 85.42 | 83.88 | Upgrade
|
| Operating Income | -17.38 | -1.82 | -29.93 | -62.47 | -63.77 | 15.39 | Upgrade
|
| Interest Expense | -3.31 | -5.21 | -8.23 | -6.58 | -4.58 | -2.59 | Upgrade
|
| Interest & Investment Income | 2.65 | 5.02 | 6.33 | 2.37 | 2.44 | 1.68 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.88 | 14.89 | -0.82 | 15.68 | -6.86 | -5.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.75 | 3.17 | 2.36 | 1.87 | 1.15 | 6.07 | Upgrade
|
| EBT Excluding Unusual Items | -22.16 | 16.05 | -30.29 | -49.13 | -71.62 | 15.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.24 | -0.02 | -0.07 | - | - | -3.89 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.04 | 0.04 | -25.59 | 0.05 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.03 | - | - | Upgrade
|
| Pretax Income | -21.96 | 16.07 | -55.95 | -49.06 | -71.62 | 11.63 | Upgrade
|
| Income Tax Expense | 2 | 4.43 | 1.08 | -4.39 | -9.17 | 4.44 | Upgrade
|
| Net Income | -23.97 | 11.64 | -57.03 | -44.66 | -62.45 | 7.19 | Upgrade
|
| Net Income to Common | -23.97 | 11.64 | -57.03 | -44.66 | -62.45 | 7.19 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -66.06% | Upgrade
|
| Shares Outstanding (Basic) | 71 | 67 | 54 | 39 | 32 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 71 | 72 | 54 | 39 | 32 | 33 | Upgrade
|
| Shares Change (YoY) | 3.81% | 34.30% | 38.27% | 19.16% | -0.13% | 0.31% | Upgrade
|
| EPS (Basic) | -0.34 | 0.17 | -1.07 | -1.15 | -1.92 | 0.22 | Upgrade
|
| EPS (Diluted) | -0.34 | 0.17 | -1.07 | -1.15 | -1.92 | 0.22 | Upgrade
|
| EPS Growth | - | - | - | - | - | -66.39% | Upgrade
|
| Free Cash Flow | -15.02 | 17.32 | -12.37 | -0.29 | -376.35 | -4.4 | Upgrade
|
| Free Cash Flow Per Share | -0.21 | 0.24 | -0.23 | -0.01 | -11.59 | -0.14 | Upgrade
|
| Dividend Per Share | 0.400 | 0.400 | 0.550 | 1.000 | - | 0.182 | Upgrade
|
| Dividend Growth | -27.27% | -27.27% | -45.00% | - | - | -60.00% | Upgrade
|
| Gross Margin | 21.72% | 20.34% | 12.08% | 4.46% | 4.60% | 16.40% | Upgrade
|
| Operating Margin | -5.60% | -0.54% | -7.79% | -14.41% | -13.55% | 2.54% | Upgrade
|
| Profit Margin | -7.73% | 3.45% | -14.83% | -10.30% | -13.27% | 1.19% | Upgrade
|
| Free Cash Flow Margin | -4.84% | 5.13% | -3.22% | -0.07% | -79.97% | -0.73% | Upgrade
|
| EBITDA | 17.11 | 10.44 | -9.98 | -37.48 | -39.81 | 38.65 | Upgrade
|
| EBITDA Margin | 5.52% | 3.09% | -2.60% | -8.64% | -8.46% | 6.39% | Upgrade
|
| D&A For EBITDA | 34.49 | 12.27 | 19.95 | 25 | 23.96 | 23.26 | Upgrade
|
| EBIT | -17.38 | -1.82 | -29.93 | -62.47 | -63.77 | 15.39 | Upgrade
|
| EBIT Margin | -5.60% | -0.54% | -7.79% | -14.41% | -13.55% | 2.54% | Upgrade
|
| Effective Tax Rate | - | 27.57% | - | - | - | 38.15% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.